

16. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein at least one of the components is in the form of a preparation of a pharmaceutically active ingredient.

17. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein at least one of the components is in the form of an extract, powder, distillate, infusion, tincture, or oil.

C¹
wel.
18. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein the least one other component is *Vitex agnus-castus*.

19. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein the least one other component is *Cimicifuga racemosa*.

20. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein the least one other component is *Vitex agnus-castus* and *Zingiber officinale*.

21. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein the least one other component is *Zingiber officinale*.

23. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein *Tanacetum parthenium* is present in an amount of 0.1-1 mg of parthenolide.

24. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein *Cimicifuga racemosa* is present is an amount of 20-100 mg.

C²
25. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein *Vitex agnus-castus* is present in an amount of 20-100 mg.

26. (Amended) The herbal pharmaceutical preparation for the treatment of migraine of claim 15, wherein *Zingiber officinale* is present is an amount of 0.5-6 g.

C²
C² 27. (Amended) A method for the treatment or prevention of migraine in a subject in need of such treatment or prevention, comprising: administering to said subject an effective amount of a preparation of *Tanacetum parthenium* in combination with at least one other component selected from the group consisting of *Vitex agnus-castus*, *Cimicifuga racemosa* and *Zingiber officinale*.

C³ 30. (Amended) The method of claim 27 wherein *Tanacetum parthenium* is present in an amount of 0.1-1 mg of parthenolide.

32. (Amended) The method of claim 27 wherein *Vitex agnus-castus* is present in an amount of 20-100 mg.

C⁴ 33. (Amended) The method of claim 27 wherein *Zingiber officinale* is present in an amount of 0.5-6 g.

34. (Amended) The method of claim 27 wherein the preparation is administered in the form of a capsule, a film coated tablet, a solution, a sugar-coated tablet, a suppository, an effervescent tablet, a chewable tablet, or an effervescent granulate.

--35. (New) The herbal pharmaceutical preparation for the treatment of migraine of claim 23, wherein the *Tanacetum parthenium* is present in an amount of 0.2 to 0.6 mg.

C⁵ 36. (New) The herbal pharmaceutical preparation for the treatment of migraine of claim 25, wherein the *Vitex agnus-castus* is present in an amount of 20 to 40 mg.

37. (New) The herbal pharmaceutical preparation for the treatment of migraine of claim 26, wherein the *Zingiber officinale* is present in an amount of 1 to 4g.

38. (New) The method of claim 30 wherein the amount of the *Tanacetum parthenium* is 0.2 to 0.6 mg.
